Magenta Therapeutics Valuation
| MGTADelisted Stock | USD 0.82 0.03 3.80% |
Today, the firm appears to be overvalued. Magenta Therapeutics secures a last-minute Real Value of $0.65 per share. The latest price of the firm is $0.82. Our model forecasts the value of Magenta Therapeutics from analyzing the firm fundamentals such as Current Valuation of (32.66 M), return on equity of -0.65, and Shares Owned By Insiders of 2.23 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Magenta Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Magenta Therapeutics is based on 3 months time horizon. Increasing Magenta Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Magenta Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Magenta Stock. However, Magenta Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.82 | Real 0.65 | Hype 0.82 | Naive 0.82 |
The real value of Magenta Stock, also known as its intrinsic value, is the underlying worth of Magenta Therapeutics Company, which is reflected in its stock price. It is based on Magenta Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Magenta Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Magenta Therapeutics helps investors to forecast how Magenta stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Magenta Therapeutics more accurately as focusing exclusively on Magenta Therapeutics' fundamentals will not take into account other important factors: Magenta Therapeutics Total Value Analysis
Magenta Therapeutics is now anticipated to have valuation of (32.66 M) with market capitalization of 45.14 M, debt of 29.96 M, and cash on hands of 128.28 M. The negative valuation of Magenta Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Magenta Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(32.66 M) | 45.14 M | 29.96 M | 128.28 M |
Magenta Therapeutics Asset Utilization
One of the ways to look at asset utilization of Magenta is to check how much profit was generated for every dollar of assets it reports. Magenta Therapeutics secures a negative usage of assets of -0.29 %, losing $0.002885 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Magenta Therapeutics shows how discouraging it operates for each dollar spent on its assets.Magenta Therapeutics Ownership Allocation
Magenta Therapeutics maintains a total of 60.66 Million outstanding shares. Over half of Magenta Therapeutics' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Magenta Therapeutics Profitability Analysis
Net Loss for the year was (76.46 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Magenta Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Magenta Therapeutics and how it compares across the competition.
About Magenta Therapeutics Valuation
The delisted stock valuation mechanism determines Magenta Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Magenta Therapeutics. We calculate exposure to Magenta Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Magenta Therapeutics's related companies.Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Magenta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 66 people.
Magenta Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 59.4 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Magenta Stock
If you are still planning to invest in Magenta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Magenta Therapeutics' history and understand the potential risks before investing.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |